Day Traders Tag icon

×
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s (NYSE: JNJ) Stelara (ustekinumab)) in adults with moderately to severely active Crohn’s disease.  The data showed that more patients achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075). Also Read: Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names. In patients with active ...


In The news